Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF in Treatment of IIM-ILD and Its Effect on Treg Cells
NCT05129410Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate mofetil in interstitial lung disease (ILD) and idiopathic inflammatory myopathy (IIM), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Forced Vital Capacity % predicted at 12 months. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
interstitial lung disease (ILD)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT05129410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129410.